In this webinar, Dr Ryan Paul discusses the newly-funded type 2 diabetes medication dulaglutide, and provides advice on when and how to use it.
Initiating treatment with empagliflozin: Algorithms, notes and talking points
When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource. Always maintain metformin treatment if tolerated.
Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. (Updated 24 August 2021).
This resource will not be available after 30 June 2024 as He Ako Hiringa is shutting down. If your organisation would like to host this resource please contact admin@akohiringa.co.nz
- Click here for an easy-to-print version.
- For more diabetes resources, click here.
- For a similar resource on initiating treatment with dulaglutide or liraglutide, click here.
Bibliography
Medsafe, New Zealand Medicines and Medical Devices Safety Authority. Jardiance (empagliflozin) data sheet. Accessed April 2021. https://www.medsafe.govt.nz/profs/Datasheet/j/jardiancetab.pdf
New Zealand Society for the Study of Diabetes (NZSSD). Type 2 Diabetes Management Guidance. Accessed April 2021. https://t2dm.nzssd.org.nz
PHARMAC. Decision to fund two new medicines for type 2 diabetes - Amended with Q&A. January 2021. Accessed April 2021. http://tinyurl.com/specauth
Zinman B, Wanner C, Lachin J et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. NEJM. 2015;373(22):2117-28